SNORD90 induces glutamatergic signaling following treatment with 1

monoaminergic antidepressants 2

- 3 4 **AUTHORS**
- Rixing Lin^{1,2,†}, Aron Kos^{3,4,5,†}, Juan Pablo Lopez^{3,4,5}, Julien Dine^{3,4,5}, Laura M. Fiori¹, Jennie 5
- 6
- 7
- Yang¹, Yair Ben-Efraim^{3,4,5}, Zahia Aouabed¹, Pascal Ibrahim^{1,2}, Haruka Mitsuhashi^{1,2}, Tak Pan Wong^{6,7}, El Cherif Ibrahim⁸, Catherine Belzung⁹, Pierre Blier¹⁰, Faranak Farzan¹¹, Benicio N. Frey^{12,13}, Raymond W. Lam¹⁴, Roumen Milev¹⁵, Daniel J. Müller^{16,17}, Sagar V. Parikh¹⁸, Claudio Soares¹⁵, Rudolf Uher^{19,20}, Corina Nagy¹, Naguib Mechawar¹, Jane A. Foster^{12,13,16}, Sidney H. Kennedy^{16,21}, Alon Chen^{3,4,5*}, and Gustavo Turecki^{1*} 8
- 9
- 10
- 11

12 AFFILIATIONS

- ¹McGill Group for Suicide Studies, Douglas Mental Health University Institute, Department of 13
- 14 Psychiatry, McGill University; Montreal, QC, Canada
- ²Integrated Program in Neuroscience, McGill University; Montreal, OC, Canada 15
- ³Department of Stress Neurobiology and Neurogenetics, Max Planck Institute of Psychiatry; 16
- Munich, Germany 17
- ⁴Department of Brain Sciences, Weizmann Institute of Science; Rehovot, Israel 18
- ⁵Department of Molecular Neuroscience, Weizmann Institute of Science; Rehovot, Israel 19
- 20 ⁶Neuroscience Division, Douglas Research Centre; Montreal, QC, Canada.
- ⁷Department of Psychiatry, McGill University; Montreal, QC, Canada. 21
- ⁸Aix-Marseille Université, CNRS, INT, Institute Neuroscience Timone; Marseille, France 22
- 23 ⁹UMR 1253, iBrain, UFR Sciences et Techniques; Parc Grandmont, Tours, France
- ¹⁰Mood Disorders Research Unit, University of Ottawa Institute of Mental Health Research; 24
- Ottawa, Ontario, Canada. 25
- 26 ¹¹eBrain Lab, Simon Fraser University; Surrey, British Columbia, Canada
- ¹²Department of Psychiatry and Behavioural Neurosciences, McMaster University; Hamilton, 27
- 28 ON, Canada
- ¹³Mood Disorders Program, St. Joseph's Healthcare Hamilton; Hamilton, ON, Canada 29
- ¹⁴Department of Psychiatry, University of British Columbia; Vancouver, British Columbia, 30 31 Canada
- 32 ¹⁵Departments of Psychiatry and Psychology, Queens University, Providence Care; Kingston,
- 33 Ontario, Canada
- 34 ¹⁶Department of Psychiatry, University Health Network, Krembil Research Institute, University
- of Toronto; Toronto, Ontario, Canada 35
- 36 ¹⁷Centre for Addiction and Mental Health; Toronto, Ontario, Canada
- ¹⁸Department of Psychiatry, University of Michigan; Ann Arbor, Michigan, USA 37
- ¹⁹Nova Scotia Health Authority; Halifax, NS, Canada 38
- ²⁰Department of Psychiatry, Dalhousie University; Halifax, Nova Scotia, Canada 39
- ²¹St Michael's Hospital, Li Ka Shing Knowledge Institute, Centre for Depression and Suicide 40
- Studies; Toronto, Ontario, Canada 41
- 42
- 43 [†]These authors contributed equally to this work
- 44
- 45 *Corresponding author. Email: gustavo.turecki@mcgill.ca
- 46

47 ABSTRACT

Most available antidepressants target the serotonergic system, selectively or non-selectively, and 48 vield slow and inconsistent clinical responses, whereas the monoamine changes they elicit do not 49 50 correlate with treatment response. Recent findings point to the glutamatergic system as a target 51 for rapid acting antidepressants. Investigating different cohorts of depressed individuals treated 52 with serotonergic and other monoaminergic antidepressants, we found that the expression of a 53 small nucleolar RNA, SNORD90, was elevated following treatment response. When we 54 increased SNORD90 levels in the mouse anterior cingulate cortex (ACC), a brain region 55 regulating mood responses, we observed antidepressive-like behaviors. We identified neuregulin 56 3 (NRG3) as one of the targets of SNORD90, which we show is regulated through the 57 accumulation of N6-methyladenosine modifications leading to YTHDF2 mediated RNA decay. 58 We further demonstrate that a decrease in NRG3 expression resulted in increased glutamatergic 59 release in the mouse ACC. These findings support a molecular link between monoaminergic 60 antidepressant treatment and glutamatergic neurotransmission.

61

62 INTRODUCTION:

63 Antidepressants are the first line treatment for major depressive disorder (MDD), collectively accounting for one of the most prescribed medications (1). However, response to antidepressant 64 65 treatment is variable with less than 50% of patients responding to first trial, and up to 40% with 66 no clinical response after two or more trials (2). While most currently available antidepressants act by selectively or non-selectively targeting serotonergic receptors the exact mechanisms by 67 which they effect mood changes and improvements in depression remain unknown. Importantly, 68 although the enhancement of monoamine function, in particular serotonin, can be observed 69 70 within hours after antidepressant drug administration, clinical improvements are not observed 71 until days or weeks following antidepressant treatment initiation (3-5). The delayed clinical 72 response led researchers to study underlying neurobiological adaptations to understand 73 mechanisms of antidepressant response. Monoamines have been a focus of depression studies since most treatment options target this system. However, given the delayed clinical response 74 75 other neurotransmitter systems have been gaining interest in depression and particularly the 76 glutamatergic system, which is believed to be the target of rapid acting antidepressants (6, 7). 77 Moreover, recent evidence suggest that monoaminergic antidepressants may act by modulating 78 the glutamatergic system, although it is still unclear through what molecular mechanisms (8, 9). 79

In this study, we identified a molecular mechanism whereby monoaminergic antidepressants
produce an effect on glutamatergic neurotransmission. We found elevated levels of a small
nucleolar RNA (snoRNA), SNORD90, in response to antidepressant drug exposure and report
that SNORD90 guides N6-methyladenosine (m6A) modifications onto neuregulin 3 (NRG3),

84 which in turn lead to YTHDF2-mediated down-regulation of NRG3 expression and subsequent
85 increases in glutamatergic release.

86

87 **RESULTS**:

88 SNORD90 levels are increased in response to monoaminergic antidepressants

89 We initially examined snoRNA expression using small RNA-sequencing data from peripheral

90 blood samples collected from three independent antidepressant clinical trials (discovery cohort,

91 replication cohort 1 and replication cohort 2) administrating duloxetine, escitalopram, or

92 desvenlafaxine. To identify snoRNAs associated with treatment response, we focused our

93 attention on snoRNAs that were differentially expressed between baseline (T0) and eight weeks

94 after treatment (T8), when clinical outcome was ascertained. In doing so, we identified nine

95 snoRNAs in our placebo controlled double blind discovery cohort that had a significant

96 interaction (p < 0.05) between time (T0/T8) and treatment outcome (response/non-response)

97 (figure 1A & supplemental table 1-3). In particular, SNORD90 was the only snoRNA that was

98 consistently up-regulated after antidepressant treatment in subjects who responded to treatment

across all three independent cohorts (figure 1B & supplemental figure 1). As such, we further

100 investigated SNORD90.

101

To better understand if SNORD90 expression has similar changes in the brain following
antidepressant treatment as observed in peripheral tissue, we investigated human post-mortem
anterior cingulate cortex (ACC), a brain region that plays an important role in the regulation of
mood (*10*, *11*). We studied individuals who died while affected with MDD and were or were not
treated with antidepressants. We observed a specific up-regulation of SNORD90 in individuals

107	who were depressed when they died and were actively treated with antidepressants (figure 1C).
108	To follow up these results, we investigated the expression of Snord90 in an unpredicted chronic
109	mild stress (UCMS) mouse model, which is commonly used to study depressive-like behaviors
110	in mice. Mice were subjected to UCMS, followed by administration of fluoxetine (12). We
111	specifically profiled the mouse cingulate area $1/2$ (cg1/2), a region that is equivalent to the
112	human ACC. Similar to the results observed in humans, we observed a specific up-regulation of
113	Snord90 in the ACC of mice that underwent the UCMS paradigm followed by antidepressant
114	administration, whereas UCMS or antidepressant administration alone did not alter the
115	expression of Snord90 (figure 1D). To assess if the effects observed on the expression of
116	SNORD90 were specific to antidepressants or common to other drugs, we treated human
117	neuronal cells derived from iPSCs and differentiated to a monoaminergic phenotype with several
118	psychotropic drugs, including duloxetine, escitalopram, haloperidol, lithium, or non-
119	psychotropic drugs (aspirin) and regular culture media. We observed that SNORD90 expression
120	was up-regulated exclusively by antidepressant drugs, while other treatments did not
121	significantly alter SNORD90 expression (figure 1E). Together our data suggests that
122	antidepressant treatment response associates with an increase in SNORD90 expression.
123	
124	SNORD90 over-expression in mouse ACC induces anti-depressive like behaviours
125	Given that we observed an upregulation of SNORD90 with antidepressant treatment response in
126	humans and mice, we next investigated if the over-expression of Snord90 in the cg 1/2 cortex of

127 mice has behavioural implications. We over-expressed (OE) Snord90 or a full scrambled

128 Snord90 sequence control in the mouse cg1/2 via bilateral injections of an adeno-associated virus

129 (AAV) followed by a battery of behavioural tests designed to measure anxiety and depressive-

130	like behaviors in mice (figure 2A). We did not observe any differences in the total distance
131	traveled in the open field test, which indicated no general locomotor differences between
132	Snord90 OE and full scramble OE (figure 2B). Snord90 OE increased the amount of time spent
133	in the open arm and decreased the amount of time spent in the closed arm of the elevated plus
134	maze (figure 2C). Moreover, Snord90 OE increased time spent grooming after splashing with
135	10% sucrose solution and increased time spent struggling in the tail suspension test (figure 2D-
136	E). Lastly, we calculated an integrated emotionality Z-score by combining data from the elevated
137	plus maze, splash test, and tail suspension test (figure 2F). Overall, our results consistently
138	showed that over-expressing SNORD90 levels in cg1/2 yielded decreased emotionality
139	indicative of a decrease in anxiety-like and depressive-like behaviours (figure 2F).
140	
141	SNORD90 directly down-regulates NRG3
142	SNORD90 is subcategorized as an orphan snoRNA as it does not have any canonical rRNA,
143	snRNA, or tRNA targets (13). However, more recent studies have indicated that some snoRNAs
144	exhibit atypical functioning such as regulation of alternative splicing and modulating expression
145	of mRNA (14-16). Thus, we explored possible RNA targets for SNORD90 using the basic local
146	alignment (BLAST) search tool for base complementarity, and using the C/D box snoRNA target
147	prediction tool "PLEXY" (17). Using these in-silico methods we identified NRG3 as a putative
148	gene target for SNORD90 (figure 3A & supplementary table 4-5). More specifically, we
149	identified three predicted binding regions for SNORD90 on the NRG3 pre-mRNA (pre-NRG3)
150	(figure 3A & supplementary table 4-5). NRG3 is a growth factor that is part of the neuregulin
151	family and that is highly enriched in the brain and has been previously associated with
152	

153	NRG3 expression in the same human and mouse ACC samples, as well as in the neuronal
154	cultures described above (supplementary figure 2A-C). We observed a negative correlation
155	between SNORD90 and NRG3 in all three experimental contexts (supplementary figure 2D-F),
156	and interestingly, we observed the most significant differences in direction of fold-change
157	between SNORD90 and NRG3 expression in groups with antidepressant drug exposure

159

158

(supplementary figure 2G-I).

160 To further investigate the relationship between SNORD90 and NRG3, we over-expressed 161 SNORD90 in human neural progenitor cells (NPCs) and assessed the resulting effects on NRG3 162 expression (supplementary figure 3A-B). We constructed AAV vectors expressing wild-type 163 SNORD90 (SNORD90 OE), as well as two scrambled controls (supplementary figure 3A). The 164 first control had a scramble sequence in the central region of the SNORD90 transcript, where the predicted complementary sequence to NRG3 lies (seed scramble OE) and the second control had 165 166 a full scramble of the entire SNORD90 transcript (full scramble OE) (supplementary figure 3A). 167 SNORD90 OE resulted in a \sim 50% decrease in NRG3 expression at both the mRNA and protein 168 levels (figure 3B and supplementary figure3C). Seed scramble OE and full scramble OE did not alter the expression of NRG3, indicating the region of predicted complementarity between 169 170 SNORD90 and NRG3 plays an important role in the ability of SNORD90 to down-regulate 171 NRG3 (figure 3B). We also measured the expression of pre-NRG3, since our in-silico 172 predictions indicated that SNORD90 is primarily interacting with intronic regions of pre-NRG3, 173 however, pre-NRG3 expression was not altered by SNORD90 OE or any of the scrambled controls (supplementary figure 3D). We next examined the effects of SNORD90 knock-down 174 175 (KD) using antisense oligonucleotides (ASO) (supplementary figure 4A-B). We screened four

176 ASOs that target different regions of SNORD90 and selected the ASO achieving the best KD 177 (supplemental figure 4A-B). SNORD90 KD by approximately 55% resulted in a ~50% 178 upregulation of NRG3 expression (figure 3C). We again did not observe any significant changes 179 at the level of pre-mRNA expression (supplementary figure 4C). Finally, to further confirm the importance of direct interaction between SNORD90 and NRG3, we designed target blockers 180 181 which have sequence complementarity to the predicted SNORD90 binding sites on pre-NRG3 182 (figure 3D). Target blockers were co-transfected with our SNORD90 OE vectors (figure 3D). 183 Interestingly, when each individual site was blocked, we observed a partial rescue of NRG3 184 expression (figure 3E). However, simultaneously blocking all three predicted sites was required 185 for a complete rescue of the downregulation effects of SNORD90 OE (figure 3E). Pre-NRG3 186 expression was not altered by any target blockers (supplementary figure 5). Together our data 187 suggests that SNORD90 directly down-regulates NRG3 expression through multiple interaction 188 sites on intronic regions.

189

190 SNORD90 associates with RBM15B and guides m6A modifications onto NRG3

191 We next asked what mechanisms may explain SNORD90's effects on NRG3 given that it 192 interacts with intronic regions of NRG3, and yet, it does not affect pre-mRNA levels of NRG3. 193 Since SNORD90 displays atypical functioning, we posited that it could regulate NRG3 through 194 the recruitment of a unique set of RNA binding proteins (RBPs) that is different from 195 canonically functioning C/D box snoRNAs (21). Using the in-silico tool "oRNAment" we 196 identified a sequence-motif for RNA Binding Motif Protein 15B (RBM15B); this motif sequence was further confirmed by Van Nostrand et al., 2020 (22, 23) (supplemental table 6). RBM15B is 197 198 a key regulator of RNA N6-methyladenosine (m6A) modifications by facilitating interactions

199 with Wilms' tumor 1-associating protein (WTAP), which in turn binds to methyltransferase like 200 3 (METTL3) forming a major m6A writer complex (24). To confirm the association of 201 SNORD90 with RBM15B, we performed RNA immunoprecipitation (RIP) against RBM15B as 202 well as the canonical core enzymatic protein for C/D snoRNAs, Fibrillarin (figure 4A) (25, 26). 203 We observed a significantly higher level of association of SNORD90 to RBM15B compared to 204 fibrillarin whereas a canonically functioning snoRNA, SNORD44, displayed enrichment for 205 fibrillarin IP (figure 4A). Furthermore, when we over-expressed SNORD90 we observed an 206 increase in association of SNORD90 with RBM15B, compared to over-expression of a 207 scrambled control (figure 4B). We did not observe an increase of SNORD90 association with 208 Fibrillarin following SNORD90 OE, indicating that SNORD90 showed preference for 209 interacting with RBM15B (figure 4B). Since snoRNAs and RBM15B are both found in the 210 nucleus this may in part explain SNORD90's role in interacting with intronic regions of NRG3 211 pre-mRNA (21, 24). Canonical snoRNAs function by guiding their partner proteins to target 212 transcripts which, in-turn, induce a chemical modification (27). Thus, we hypothesized that 213 SNORD90 is likely acting as a guide RNA for RBM15B and its associated m6A writer complex, 214 resulting in an increase in m6A levels on NRG3. To test this hypothesis, we measured total m6A 215 abundance on NRG3 and pre-NRG3 transcripts from our SNORD90 OE in-vitro NPC culture 216 experiments detailed above. We observed an increase of m6A abundance on both NRG3 and pre-217 NRG3, following SNORD90 OE, whereas seed scramble OE and full scramble OE did not alter 218 m6A abundance (figure 4C-D). Furthermore, introducing target blockers blunted the increase of 219 m6A abundance on both NRG3 and pre-NRG3 (figure 4E-F). To further test RBM15B's role in 220 the observed increase in m6A levels on NRG3, we used dicer-substrate short interfering RNAs 221 (dsiRNAs) to knock-down RBM15B (RBM15B KD) (supplementary figure 6). RBM15B KD

222 followed by SNORD90 OE blunted the increase of m6A levels on NRG3 and pre-NRG3 (figure 223 4G-H). RBM15B KD also blunted the decrease of NRG3 expression following SNORD90 OE 224 (figure 4G-H). Interestingly we observed a significant negative correlation between m6A levels 225 and expression of NRG3, but this was not observed for pre-NRG3, which could possibly be 226 explained by the fact that m6A-readers are primarily located in the cytoplasm, and thus would 227 only recognize the m6A-modifications of the mature NRG3 transcript and promote its decay 228 when it is shuttled out of the nucleus into the cytoplasm (supplementary figure 7). Ke et al., 2017 229 demonstrated that m6A modifications are added onto nascent pre-mRNA during transcription 230 (28). Moreover, m6A levels remain unchanged between nascent pre-mRNA and steady-state 231 mRNA in the cytoplasm (28). Our results further support these findings as it is possible that 232 SNORD90 is guiding m6A modifications onto NRG3 at the pre-mRNA level, which are retained 233 in the mRNA molecule. Although it is unclear why SNORD90 targets intronic regions, while it 234 seems that m6A modifications are deposited onto exonic regions, this could perhaps be explained 235 by the secondary structure of the RNA molecule where exonic regions could be looping closer to 236 the SNORD90-guided methylation complex.

237

238 The YTH family of proteins are the best described readers of RNA m6A modifications. The

239 YTH family includes: YTHDF1, YTHDF2, YTHDF3, YTHDC1, and YTHDC2. Of these,

240 YTHDF1, YTHDF2 and YTHDF3 regulate RNA stability, whereas functional implications for

241 YTHDC1 and YTHDC2 are less well defined (29, 30). Furthermore, YTHDF1, YTHDF2,

242 YTHDF3, and YTHDC2 are primarily located in the cytoplasm, whereas YTHDC1 is primarily

located in the nucleus (31). We selectively knocked-down each of the above-mentioned m6A-

244 readers using dsiRNAs followed by SNORD90 OE to elucidate which m6a-reader(s) are

245	involved in the down-regulation of NRG3 (figure 4I &supplementary figure 8). Although
246	YTHDF1 KD, YTHDF2 KD, and YTHDF3 KD all showed the ability to blunt the decreased
247	NRG3 expression following SNORD90 OE, YTHDF2 displayed the most robust ability to blunt
248	this effect, recovering NRG3 expression to WT patterns (figure 4I). On the other hand, YTHDC2
249	KD and YTHDC1 KD did not blunt the decrease of NRG3 expression after SNORD90 OE;
250	displaying similar patterns of NRG3 expression to SNORD90 OE with a dsiRNA scramble
251	control (siControl) (figure 4I). Interestingly, YTHDC1 KD, the nuclear m6a-reader, resulted in a
252	decrease of pre-mRNA levels of NRG3 expression compared to WT, while knock-down of all
253	other m6a-readers had no significant effect on pre-NRG3 expression levels (supplementary
254	figure 9). Together this evidence supports the hypothesis that 1) SNORD90 increases NRG3
255	m6A transcript methylation and subsequent decay, and 2) that the decay occurs primarily in the
256	cytoplasm (figure 4J). This, in turn, explains why we only observed changes in NRG3 mRNA
257	and protein levels, but did not observe changes in pre-mRNA levels following SNORD90 OE.
258	
259	SNORD90 mediates down-regulation of Nrg3 resulting in increased glutamatergic
260	· · · · · ·

260 neurotransmission

We next investigated the functional relevance of decreased NRG3 expression in-vivo. NRG3 has previously been shown to interact with syntaxin, disrupting SNARE complex formation in the presynaptic terminal, and inhibiting vesicle docking (19). Nrg3 knock-out resulted in increased probability of glutamate release in mouse hippocampal neurons (19). To investigate if SNORD90-mediated down-regulation of NRG3 has a similar effect in mice, we first investigated if SNORD90's ability to down-regulate NRG3 is conserved in mice. We performed in-silico target prediction between mouse Snord90 and Nrg3 using "PLEXY" (supplementary table 7).

268	Although predicted sequence complementary sites between Snord90 and Nrg3 are not as robust
269	as in humans, there is conservation between the two species (supplementary table 7 and
270	supplementary figure 10). To further explore this effect, we over-expressed Snord90 or a full
271	scrambled control in the mouse ACC (cg1/2) via bilateral injections of an AAV virus (figure
272	5A). RT-qPCR confirmed successful over-expression of Snord90 and subsequent down-
273	regulation of Nrg3 in mice (figure 5B). Next, we performed whole-cell patch-clamp recordings
274	from pyramidal neurons of the ACC in acute brain slices from mice over-expressing Snord90 or
275	the full scramble control. We observed an increase in spontaneous excitatory postsynaptic
276	currents (sEPSC) frequency following Snord90 OE compared to full scramble control without
277	any effect on sEPSC amplitude (figure 5C-E). This increase in glutamatergic neurotransmission
278	is likely due to an increase in glutamate release probably resulting from NRG3 pre-synaptic
279	expression and effect on SNARE complex (19). Together this indicates that SNORD90-mediated
280	down-regulation of NRG3 has implications in glutamate neurotransmission, which translates to
281	behavioral changes such as anxiolytic and anti-depressive-like behaviors.
282	
283	DISCUSSION:
284	In this study, we demonstrated that SNORD90 mediates antidepressant drug action through
285	regulation of NRG3. While it is unclear how serotonergic antidepressant drugs may promote the
286	increase of SNORD90 expression, one possible mechanism may be through histone
287	serotonylation. Previous studies have demonstrated that serotonin can covalently attach to
288	histone H3 and influence gene expression (32). The administration of serotonergic

antidepressants could change intracellular monoamine levels influencing the expression of

290 SNORD90; however, future studies are needed to investigate this hypothesis. Our results indicate

291 that SNORD90 associates with RBM15B and is involved in mediating m6A modifications, 292 specifically onto NRG3. This is a slight but significant divergence from canonically functioning 293 C/D box snoRNAs that are known to associate with fibrillarin, a methyltransferase responsible 294 for 2'O-methylation (2'OMe) (33, 34). Whereas 2'OMe can occur on the ribose of any base and 295 is associated with increased RNA stability, m6A is an adenosine specific modification with a 296 diverse range of effects on RNA stability (31, 35). Specifically, our data show that increased 297 m6A levels elicit NRG3 decay through recognition by the m6A reader YTHDF2. Furthermore, SNORD90's influence on NRG3 appears to bridge a relationship between the monoaminergic 298 299 and the glutamatergic systems. Many studies have shown that antidepressant drugs target the 300 monoaminergic system but also affect the glutamatergic system (9). However, it has not been 301 clear until now what is mediating these effects, though they have often been attributed to off 302 target binding of antidepressant drugs. Our study offers molecular evidence supporting one 303 particular mechanism that might mediate the link between serotonin targeting drugs and 304 activation of the glutamatergic system. Although NRG3 expression has been associated with 305 psychiatric disorders including MDD, it has not previously been associated with antidepressant 306 treatment (18). NRG3 is primarily expressed in excitatory pyramidal neurons, and accordingly, 307 the increase of SNORD90 in response to antidepressant treatment, can yield specific effects on 308 excitatory glutamatergic neurons and thus glutamatergic neurotransmission (19, 36). Gaining a 309 better understanding of the molecular mechanisms of antidepressant treatment response will 310 offer new targets for the development of more effective treatments of MDD.

311

312 MATERIALS AND METHODS:

313 <u>Human Clinical trial Subjects</u>

Three independent cohorts were used in this study, comprising 660 individuals (37-39).

315

316	Cohort 1 (N=258) was obtained in collaboration with Lundbeck A/S sponsored clinical trials and
317	is composed of individuals diagnosed with MDD in a current major depressive episode (MDE)
318	who were enrolled in a double-blind clinical trial and received treatment with either duloxetine
319	(60mg), a serotonin-norepinephrine reuptake inhibitor (SNRI), or placebo for eight weeks. For
320	each patient, peripheral blood samples were collected at baseline (T0) and after treatment (T8).
321	Participants, aged 19-74 years, were recruited based on a primary diagnosis of MDD and MDE
322	lasting at least 3 months, with a severity score on the Montgomery-Åsberg Depression Rating
323	Scale (MADRS) of \geq 22 at T0. Participants resistant to at least two previous AD treatments or
324	who had received electroconvulsive therapy in the 6 weeks before the study began were
325	excluded. Other exclusion criteria included: MDE in bipolar disorder, presence of psychotic
326	features, and recent substance use disorder. This clinical trial was approved by ethics boards of
327	participating centers, and all participants provided written informed consent.
328	www.ClinicalTrials.gov (11984A NCT00635219; 11918A NCT00599911; 13267A
329	NCT01140906). For more details, please refer methods section of Lopez et al., 2017 (37).
330	
331	Cohort 2 (N=236) was obtained in collaboration with the Canadian Biomarker Integration
332	Network in Depression (CAN-BIND) and is composed of individuals diagnosed with MDD
333	(N=153) and healthy controls (N=83). Patients and controls were recruited at six Canadian
334	clinical centers. Exclusion criteria included personal and family history of schizophrenia or
335	bipolar disorder, or current substance dependence. Depressed patients were treated with
336	escitalopram (10-20mg per day), a selective serotonin reuptake inhibitor (SSRI), for eight weeks.

Depression severity was assessed at baseline and after treatment by MADRS. This trial was
approved by ethics boards of participating centers and all participants provided written informed
consent. www.ClinicalTrials.gov identifier NCT01655706. Registered 27 July 2012. For more
details, please refer to Kennedy et al., 2019 (*38*).

341

342 Cohort 3 (N=166) was obtained at the Douglas Mental Health University Institute and is 343 composed of healthy controls (N=28) and individuals diagnosed with MDD (N=138) who were 344 enrolled in the community outpatient clinic at the Douglas Mental Health University Institute. 345 Depressed patients were treated with either desvenlafaxine, a serotonin-norepinephrine reuptake 346 inhibitor (SNRI) or escitalopram, a selective serotonin reuptake inhibitor (SSRI). For each 347 patient, a blood sample was taken at baseline before treatment administration and 8 weeks post-348 treatment. Participants (healthy controls and individuals with MDD) were excluded from the 349 study if they had comorbidity with other major psychiatric disorders, if they had positive tests for 350 illicit drugs at any point during the study, or if they had general medical illnesses. Individuals 351 with MDD were not receiving antidepressant treatment at the onset of the trial, and received a 352 diagnosis of MDD without psychotic features, according to the Statistical Manual of Mental 353 Disorders, Fourth Edition (DSM-IV). Control subjects were excluded if they had a history of 354 antidepressant treatment. Eligible participants were randomized to either desvenlafaxine (50-355 100mg) or escitalopram (10-20mg) treatment. All subjects included in the study provided 356 informed consent, and the project was approved by The Institutional Review Board of the 357 Douglas Mental Health University Institute. For more details, please refer to Jollant et al., 2020 (39). 358

359

360 Clinical Assessment

All participants from all cohorts were assessed for depression severity after 6 to 8 weeks of
treatment. To quantify treatment response, we calculated percentage change of MADRS scores
(from baseline to after treatment). We used percentage change to correct for the potential effects
of differential baseline scores. Additionally, we classified participants as responder/non-

365 responder based on >50% decrease in MADRS scores from baseline.

366

367 Human peripheral blood sample processing and RNA Extraction

368 Peripheral blood samples from cohort 1 were collected in PAXgene blood RNA tubes

369 (PreAnalytix). Total RNA was isolated from whole blood using the PAXgene Blood miRNA Kit

370 (Qiagen, Canada) according to the manufacturer's instructions. Peripheral blood samples from

371 cohort 2 and cohort 3 were collected in EDTA blood collection tubes and passed through

372 LeukoLOCK filters (ThermoFisher) to capture the total leukocyte population, eliminating red

blood cells, platelets, and plasma. Filters, containing leukocytes, were frozen at -80C for storage

until ready for sample processing. Total RNA was extracted using a modified version of the

375 LeukoLOCK Total RNA Isolation System protocol (ThermoFisher). All samples were treated

376 with DNase digestion during RNA purification using the RNase-Free DNase kit (Qiagen). RNA

377 yield and quality were determined using the Nanodrop 1000 (Thermo Scientific, USA) and

378 Agilent 2200 Tapestation (Agilent Technologies, USA).

379

380 Library Construction and Small RNA-Sequencing

381 Libraries for cohort 1 and cohort 3 were prepared using the Illumina TruSeq Small RNA

382 protocol following the manufacturer's instructions. Libraries for cohort 2 were prepared using

383 NEB small RNA protocol following manufacturer's instructions. All libraries were purified 384 using biotinylated magnetic AMPure beads that allow for selection of specified complementary 385 cDNA products bound to streptavidin. A total of 50µl of amplified cDNA were mixed and 386 purified twice with AMPure XP beads in a 1.8:1 ratio (beads/sample). Cohort 1 was sequenced 387 using Illumina HiSeq2500, cohort 2 was sequenced using Illumina HiSeq4000, and cohort 3 was 388 sequenced using Illumina HiSeq2000. All samples were sequenced at the McGill University and 389 Genome Quebec Innovation Centre (Montreal, Canada) using 50 nucleotide single-end reads. All 390 sequencing data was extracted from FASTQ files and processed using CASAVA 1.8+. Illumina 391 adapter sequences were trimmed using the Fastx toolkit, and additionally filtered by applying 392 the following cut-offs: (1) Phred quality (Q) score higher than 30, (2) reads between 15-40nt in 393 length, (3) adapter detection based on perfect-10nt match, and (4) removing reads without 394 detected adapters. Bowtie35 (John Hopkins University) was used to align reads to the human 395 genome (GRCh37). Furthermore, Rfam database was used to map reads to known small 396 nucleolar RNAs. Sequencing data was normalized with the Bioconductor-DESeq2 package. 397

398 Statistical analysis

For each subject in these trials, samples collected before administration of an antidepressant (T0) and eight weeks following antidepressant treatment (T8) were analyzed according to response to treatment based on MADRS score changes. For the discovery cohort, antidepressant treated, and placebo treated subjects were analyzed separately.

403

404 A two-way mixed multivariable analysis of variance (2WM-MANOVA) was used to identify

405 snoRNAs that had a significant interaction between treatment response (response/non-response)

406	and treatment course (T0/T8). For cohort 1, antidepressant treated, and placebo treated subjects
407	were analyzed separately. All detected snoRNAs were assessed in cohort 1. Only snoRNAs that
408	showed significant interactions were assessed in cohort 2 and subsequently only snoRNAs that
409	were replicated in cohort 2 were assessed in cohort 3. For all cohorts, outliers were identified
410	using boxplot methods with values above quartile 3 (Q3) + 1.5 interquartile range (IQR) or
411	below quartile 1(Q1) - 1.5IQR (IQR=Q3-Q1). Shapiro-Wilk test and QQ plots were used to
412	assess data normality. All above mentioned tools were apart of publicly available R package
413	"rstatix" (<u>https://CRAN.R-project.org/package=rstatix</u>) (40).
414	
415	Unpredicted chronic mild stress (UCMS) mouse model:
416	Eight-week old male BALB/c mice (N=23; Centre d'Elevage Janvier, Le Genest St. Isle, France)
417	were divided into four groups as described by Herve et al., 2017 (12). In brief, control group (N
418	= 5) was kept in standard housing conditions for 8 weeks. UCMS only group ($N = 7$) comprised
419	of mice subjected to the Unpredictable Chronic Mild Stress (UCMS) procedure for 8 weeks.
420	UCMS-flx group (N=5) included mice that were subjected to the UCMS procedure for 8 weeks
421	and treated in parallel by fluoxetine (flx) during the last 6 weeks. Flx only group ($N = 6$)
422	included mice that did not undergo the UCMS procedure but were treated with fluoxetine during
423	the last 6 weeks. Mice from the control and flx only groups were housed in standard cages,
424	whereas the UCMS-exposed mice were isolated in individual home cages with no physical
425	contact with other mice. The stressors used were varied and applied in a different sequence each
426	week to avoid habituation.
427	

428 Stressors consisted of housing on damp sawdust (about 200 mL of water for 100 g of sawdust), 429 sawdust changing (replacement of the soiled sawdust by an equivalent volume of new sawdust), 430 placement in an empty cage (usually the home cage of the subject, but with no sawdust), 431 placement in an empty cage with water (the mouse is placed in its empty cage, whose bottom has been filled up with 1 cm high water at 21°C), switching cages (also sometimes termed as social 432 stress: the mouse from a cage A is placed in the soiled cage from mouse B, mouse B itself being 433 434 absent in order to avoid aggressive interactions), cage tilting (45°), predator sounds, introduction 435 of rat or cats feces as well as fur in the mouse home cage, inversion of the light/dark cycle, lights 436 on for a short time during the dark phase or light off during the light phase, confinement in small 437 tubes (diameter: 4 cm; length: 5 cm). 438 439 Mice Behavior 440 Weight and coat state were measured weekly, as markers of UCMS-induced depressive-like 441 behavior, except for the last week before sacrifice, when coat state from seven different areas of 442 the body was recorded twice, separated by 3-day intervals. At the end of the 8th week, a complementary test of nest building was performed just before sacrifice. The test was 443 administered by isolating mice in their home cages. For additional details please refer to Herve et 444 445 al., 2017 (12). 446 447 Quantification and statistical analysis

448 Details related brain dissection and RNA extraction can be found at Herve et al., 2017 (*12*). RNA
449 was reverse-transcribed using M-MLV Reverse Transcriptase (200 U/μL) (ThermoFisher) with

450 random hexamers. SNORD90 and NRG3 were quantified by RT-PCR using SYBR green

(Applied Biosystems). Reactions were run in triplicate using the QuantStudio 6 Flex System and
data collected using QuantStudio Real-Time PCR Software v1.3. One-way ANOVA was used as
described above.

454

455 <u>Human Post-Mortem Brain</u>

456 Post-mortem samples of dorsal ACC (Brodmann Area 24) were obtained, in collaboration with

457 the Quebec Coroner's Office, from the Douglas-Bell Canada Brain Bank (Douglas Mental

458 Health University Institute, Montreal, Quebec, Canada). Groups were matched for post-mortem

459 interval (PMI), pH and age. Psychological autopsies were performed as described previously,

460 based on DSM-IV criteria (41). The control group had no history of major psychiatric disorders.

461 All cases met criteria for MDD or depressive disorder not-otherwise-specified. Written informed

462 consent was obtained from next-of-kin. This study was approved by the Douglas Hospital

463 Research Centre institutional review board.

464

465 **RNA-sequencing**

466 RNA was extracted from all brain samples using a combination of the miRNeasy Mini kit and

the RNeasy MinElute Cleanup kit (Qiagen), with DNase treatment, and divided into small

468 (<200 nt) and large (>200 nt) fractions. RNA quality, represented as RNA Integrity Number, was

469 assessed using the Agilent 2200 Tapestation. Small RNA-seq libraries were prepared from the

470 small RNA fraction, using the Illumina TruSeq Small RNA protocol following the

471 manufacturer's instructions. Samples were sequenced at the McGill University and Genome

472 Quebec Innovation Centre (Montreal, Canada) using the Illumina HiSeq2000 with 50nt single-

473 end reads. All sequencing data were processed using CASAVA 1.8 + (Illumina) and extracted

474	from FASTQ files. The Fastx_toolkit was used to trim the Illumina adapter sequences.
475	Additional filtering based on defined cutoffs was applied, including: (1) Phred quality (Q) mean
476	scores higher than 30, (2) reads between 15 and 40 nt in length, (3) adapter detection based on
477	perfect-10nt match, and (4) removal of reads without detected adapter. In addition, we used
478	Bowtie [24] to align reads to the human genome (GRCh37). Furthermore, all sequencing data
479	was normalized with the Bioconductor—DESeq2 package, using a detection threshold of 10
480	counts per snoRNA. We retained all snoRNAs with >10 reads in 70% of either group (controls,
481	cases) for differential analyses. RNA extractions, sequencing, and data processing were
482	conducted by blinded investigators. For additional details please refer to Fiori et al., 2020 (42).
483	
484	Statistical analysis
485	Using toxicology screens, each sample was separated into the following groups: MDD with
486	presence of antidepressants, MDD with presence of non-antidepressant drugs, MDD with
487	negative toxicology screen, controls with non-antidepressant drugs, and controls with negative
488	toxicology screens. No control samples were positive for antidepressant drugs. For this analysis
489	we only investigated the expression for SNORD90 from this small RNA sequencing dataset.
490	NRG3 was measured via qPCR from cDNA converted from the same RNA aliquot for each
491	sample. Analysis was performed in R using "rstatix" as mentioned above employing a one-way
492	ANOVA. Shapiro-Wilk test and QQ plots were used to assess data normality.
493	
494	Human hindbrain NPC Culture and neuronal differentiation
495	Monoamine producing neurons were generated from human induced pluripotent stem cells

496 (iPSCs), using a protocol adapted from Lu et al. 2016 (43). Human iPSCs were first cultured in

497	DMEM/F12 (Gibco) supplemented with N2 (Gibco), B27 (Gibco), nonessential amino acids
498	(Gibco), 1% GlutaMAX (Gibco), 2 uM SB431542 (STEMCELL Tech.), 2uM DMH1 (Tocris),
499	and 3uM CHIR99021 (Tocris); collectively referred to as SDC media. Culturing in SDC media
500	for 1 week induces human iPSC differentiation into rostral hindbrain neural stem cells (NSCs).
501	Rostral hindbrain NSCs colonies were selected and re-plated in SDC media supplemented with
502	1000 ng/ml of SHH C25II (GenScript). Hindbrain NPCs were GBX2, HOXA2, and HOXA4
503	positive as assessed via quantitative RT-PCR to confirm hindbrain specificity at this
504	developmental stage. Ventral rostral hindbrain NSC colonies were collected and re-plated in
505	SDC + SHH media along with 10ng/ml of FGF4 (PeproTech). SDC + SHH + FGF4 media will
506	induce ventral rostral hindbrain NSC differentiation into neural progenitor cells (NPCs) after 1
507	week. NPCs were expanded in SDC+SHH+FGF4 media and differentiated into monoamine
508	producing neuron-like cells. NPCs were differentiated, for 1 month, into neuron-like cells in
509	neurobasal media (Gibco) supplemented with N2, B27, NEAA, 1ug/ml laminin (Sigma), 0.2mM
510	vitamin C (Sigma), 2.5uM DAPT (Sigma), 10ng/ml GDNF (GenScript), 10ng/ml BDNF
511	(GenScript), 10ng/ml insulin-like growth factor-I (Pepro Tech), and 1ng/ml transforming growth
512	factor β 3 (Pepro Tech). Post-differentiation, neuron-like cells underwent high-performance
513	liquid chromatography (HPLC) to test for monoamine production. HPLC confirmed production
514	of norepinephrine (NE), epinephrine (epi), dopamine (DA), and serotonin (5-HT). All NPCs and
515	differentiated NPCs were seeded on culture plates coated with 100ug/mL poly-L-ornithine
516	(sigma) and 10ug/mL laminin (Sigma) and grown in a 5% CO2 humidified incubator at 37°C.
517	

519	Cells were sonicated in 60uL of 0.25 N perchloric acid. Protein and cellular debris were cleared
520	by centrifugation at 11,000g at 4°C for 10 min. Pellets were re-suspended in 100µl of 0.1N
521	NaOH. 20uL of tissue homogenates, cleared of protein and debris, was injected using a
522	refrigerated ultiMate 3000 rapid separation autosampler (ThermoFisher) into a HPLC system
523	consisting of a luna 3 u C18 (2) 100 A 75 X 4.6 mm phenomemex and a coulometric
524	electrochemical detector (ThermoFisher) to quantify monoamines. Oxidation and reduction
525	electrode potentials of the analytical cell (5014B; ThermoFisher) were set to $+300$ and -250 mV
526	respectively. The mobile phase consisting of 73.4mM sodium acetate trihydrate, 66.6mM of
527	citric acid monohydrate, 0.025mM Na2EDTA, 0.341mM 1-octanesulfonic acid, 0.71mM of
528	Triethylamine and 6% (v/v) methanol (pH adjusted to 4.0-4.1 with acetic acid) was pumped at
529	1.5 ml/min by a solvent delivery module (dionex ultimte 3000 rs pump).

530

531 <u>NPC Drug Treatment</u>

532 Human NPCs were screened for cytotoxic effects using the MTT assay, and antidepressants were

applied at nontoxic concentrations as described by Lopez et al., 2014 (44). NPCs were cultured

534 in 24 well plates and differentiated, for 2 weeks, into neuron-like cells in neurobasal media

535 (Gibco) supplemented with N2, B27, NEAA, 1 µg/ml laminin (Sigma), 0.2 mM vitamin C

536 (Sigma), 2.5 µM DAPT (Sigma), 10 ng/ml GDNF (GenScript), 10 ng/ml BDNF (GenScript),

537 10 ng/ml insulin-like growth factor-I (Pepro Tech), and 1 ng/ml transforming growth factor β 3

538 (Pepro Tech). Following 2 weeks of differentiation, culture media was supplemented with

539 escitalopram (Sigma-Aldrich, E4786; 100 μM), duloxetine (Sigma-Aldrich, Y0001453; 10 μM),

haloperidol (Sigma-Aldrich, H1512; 10 μM), lithium (Sigma-Aldrich, L4408; 1 mM), Aspirin

541 (Sigma-Aldrich, A5376; 1mM), or left untreated (controls). Cells for each drug treatment were

- 542 incubated for 48 h before harvest and RNA extractions. Each drug treatment was performed in
- 543 triplicate. RNA was extracted using the Zymo DirectZol RNA Extraction kit. cDNA construction
- and RT-qPCR were as described above. One-way ANOVA analysis was performed in IBM
- 545 SPSS Statistics version 27 using Dunnett's post-hoc correction.
- 546

547 SNORD90 over-expression in mice:

- 548 Male CD-1 (ICR) were housed in temperature-controlled ($23 \pm 1^{\circ}$ C), constant humidity ($55 \pm$
- 549 10%), 12-hour light/dark cycle and in specific-pathogen-free conditions. Animals had access to
- 550 food and water *ad libidum*. Animals were housed in groups of four. All animal experiments were
- evaluated and approved by the local commission for the Care and Use of Laboratory Animals of
- the Government of Upper Bavaria, Germany.
- 553

554 Cloning

The Snord90 sequence was obtained from the Ensembl genome browser database (Ensemble ID
ENSMUSG00000077756). The control sequence was generated by scrambling the Snord90 gene

- using siRNA wizard software (Invitrogen). Each fragment was designed to have KpnI and
- 558 BamHI and a 10-nucleotide long overhang with the vector backbone at the 5' and 3' ends
- respectively. Each gene fragment was inserted into a KpnI with BamHI linearized pAAV-EF1a-
- 560 eGFP-H1 backbone using Gibson Assembly (NEB) according to the manufacturer's protocol.
- 561 This generated the following two vectors, pAAV-EF1a-eGFP-H1-Scramble and pAAV-EF1a-
- 562 eGFP-H1-Snord90. All plasmids were checked for mutations by DNA sequencing.
- 563
- 564 SNORD90 sequence (mouse):

565 5'AAATAATGTTTTTAAGTGTCTAGTGATGAATTTCATAGGGCAGATTCTGAGGTGAA 566 AATTTAGTTCATCATTGATTGTCCTATTATGAAATCTGAAGACACTTGAAAAACTA 3' 567 568 Scrambled sequence (mouse): 569 5'GATATTATAACGATTGTTGTATAATCTATTAGAGTGTATCGTAGGCAATGGCTATA

570 TGTAAATGTAACGTATTGTACTCGTATGATTAATTACATAATACGAATACGCTAG 3'

571

572 Validation of constructs

573 Mouse neuroblastoma neuro2a (N2a) cells were maintained at 37° C with 5% CO₂ in Minimum

574 Essential Medium (MEM), 1x Glutamax, supplemented with 1x non-essential amino acids, 1mM

575 sodium pyruvate, 100 U/ml penicillin, 100 μg/ml streptomycin and 10% fetal bovine serum

576 (FBS, Gibco). Cells were detached with trypsin and transfected using ScreenfectA (ScreenFect

577 GmbH) according to the manufacturer's protocol. Cells were fixed with 4% PFA-PBS solution

and embedded with Fluoromount-G mounting medium containing DAPI (SouthernBiotech).

579 Cells were imaged using an Axioplan 2 fluorescent microscope (Zeiss).

580

581 Virus production

582 Human embryonic kidney cells (HEK293) were cultured in Dulbecco's Modified Eagle Medium

583 (DMEM) supplemented with 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin

584 (Invitrogen) in a 5% CO₂ humidified incubator at 37°C. Cells were transfected with the gene

transfer rAAV plasmid combined with the helper plasmids in an equal molar ratio of 1:1:1 using

586 1 mg/ml linear polyethylenimine hydrochloride (PEI). The rAAV (serotype 1/2) particles were

587 harvested three days after transfection by lysing the cells with three consecutive freeze-and-thaw

588	cycles using an ethanol on dry ice bath and 37°C water bath. Lysates were centrifuged (3000 rcf)
589	followed by purification of the rAAV particles using a Heparin Agarose Type I chromatography
590	column (Sigma). The eluted rAAV particles were PBS washed using a 100000 MWCO Amicon
591	Ultra Filter (Millipore) and suspended in a final volume of 100µl. The number of viral genomic
592	particles was determined using quantitative RT-PCR resulting in the following titers; AAV1/2-
593	EF1a-eGFP-H1-Scramble 1,67x10 ¹¹ genome particles (gp)/ μ l and AAV1/2-EF1a-eGFP-H1-
594	Scramble 5×10^{10} gp/µl.

595

596 Stereotactic surgery

597 Eight-week-old mice were anesthetized with isoflurane and placed in the stereotactic apparatus 598 (TSE Systems) on a 37°C heating pad. Pre-surgery, mice were given Novalgin (200 mg/kg body 599 weight) and Metacam (sub-cutaneous 0.5 mg/kg body weight). During surgery, mice were 600 continuously supplied with 2% v/v isoflurane in O₂ through inhalation. Viruses were injected 601 bilaterally using a 33-gauge injection needle with a 5 µl Hamilton syringe coupled to an 602 automated microinjection pump (World Precision Instruments). Virus was delivered at a rate of 0.1 µl/min, to inject 0.25 µl for behavior experiments, and 0.5 µl for molecular experiments. The 603 604 injection coordinates were determined using the Franklin and Paxinos mouse brain atlas, from 605 bregma: ML +/-0.3 mm bilateral; AP +1.2 mm; DV -1.8 mm. After injection the needle was 606 retracted 0.01 mm and kept at the site for 2.5 minutes, followed by slow withdrawal. In all 607 experiments, each group consisted of two scramble control virus injected and two Snord90 608 overexpression virus injected animals. After surgery, the animals received Metacam for the 3 following days (intraperitoneal 0.5 mg/kg body weight). In all experiments, mice were tested or 609 610 tissue was extracted 3-4 weeks after surgery. After completion of the experiments, mice were

611	sacrificed by isoflurane overdose. For imaging of brain material, the brains were removed and
612	fixed in 4% PFA-PBS followed by dehydration in 30% sucrose-PBS solution for at least 24
613	hours each. Brains were sectioned (50 μ m) using a vibratome (HM 650 V, Thermo Scientific).
614	Brain slices were imaged using the VS120-S6-W slide scanner microscope (Olympus). Injection
615	sites were verified based on green fluorescent protein (GFP) expression. For RNA extraction, the
616	brains were extracted and snap-frozen using methylbutane. Brains were sectioned in 200 μ m
617	thick slices in a cryostat and the injection site was collected using 0.8 mm thick puncher. The
618	tissue was stored at -80°C until RNA extraction.
619	
620	Real-time PCR (RT-PCR)
621	Total RNA was extracted from cells or tissue using the miRNeasy Mini Kit (Qiagen). cDNA was
622	generated using the high-capacity cDNA RT kit with RNase inhibitor (Applied Biosystems)
623	according to the supplied protocol. RT-PCR was performed according to the manufacturer's
624	instructions using the QuantiFast SYBR green PCR Kit (Qiagen). RT-PCR data was collected on
625	the QuantStudio 7 Flex Real-Time PCR System (Applied Biosystems). Absolute expression
626	differences were calculated using the standard curve method. See supplementary table 8 for a list
627	of primer sequences used.
628	
629	Behavioral tests
630	For all behavioral tests, animals were brought into the room 30 minutes prior to the start of the
631	test to habituate the animals to the test room.
c	

632

633 Open field (OF) test: The OF test was performed in a 50 x 50 cm light grey box, evenly

634 illuminated with low light conditions (<10 lux). Mice were placed in the open field facing one of

the walls and recorded for 6 minutes. Animals were tracked using ANY-maze software

636 (Stoelting). Total distance traveled was used as measure of animal locomotion.

637

Elevated plus maze (EPM): EPM apparatus was made of light grey material, and consists of four 638 639 intersecting arms elevated approximately 30 cm above the floor. The two opposing open (27.5 x 640 5 cm) and closed arms (27.5 x 5 x 20 cm) are connected with a central zone (5 x 5 cm). The 641 animals were placed in the center of the EPM, facing one of the open arms and recorded for 6 642 minutes. The closed arms were illuminated with <10 lux, while the open arms were illuminated 643 with 25-30 lux. Recordings were tracked and analyzed with ANYmaze software. Total time 644 spent in the open or closed arms was used as an anxiety measure. 645 646 Splash test (Spl): Animals were placed in a novel cage containing fresh bedding material and

648 10% sucrose water at the rear of their body. Animals were recorded for 6 minutes under low-

were allowed to explore for 5 minutes. Each animal received two sprays of room temperature

649 light conditions (<10 lux). The total groom time within the 3-6 minute timeframe was manually650 scored using Solomon Coder software.

651

647

Tail suspension test (TST): In the TST, animals were taped by their tales on a metal rod,

approximately 30 cm above the ground, and illuminated with 30-35 lux. Animals were recorded

654 for 6 minutes and struggle time was quantified using ANY-maze software. The total time an

animal struggled within the 3-6 minute timeframe was used as a measure of a depression-like

656 emotional state.

657

658 Z-scoring was used to integrate multiple behavioral tests as previously described (45). First, the

659 z-score of each individual behavioral parameter was calculated.

660

$$z = \frac{X - \mu}{\sigma}$$

661

662 The z-scores of the EPM open arm, EPM closed arm, Spl and TST were combined to calculate663 an integrated emotionality score.

664

$$Emotion \ z \ score = \frac{Z_{EPM} + Z_{Spl} + Z_{TST}}{Number \ of \ tests}$$

665

The final integrated score is associated with anxiety and depressive-like behaviors with a higher
score indicating a higher emotional state, while a lower score indicating a lower emotional state.

669 <u>Target Prediction</u>

670 The entire sequence of SNORD90 was used to blast against the human genome allowing G-T

671 wobble base pairing and one mismatch base pairing (supplemental table 4). Additionally, the

672 C/D box snoRNA target prediction algorithm PLEXY, using default parameters, was used for

target prediction of SNORD90 (17). SNORD90 mature sequence was used as the input snoRNA

and target sequence input was the entire human transcriptome using both mRNA and pre-mRNA

675	sequences download	led from the	Ensembl ge	enome browser	database (supplementa	ary table 5).
-----	--------------------	--------------	------------	---------------	------------	-------------	---------------

- 676 Prediction was conducted using whole transcriptomics as well as a targeted analysis for NRG3.
- 677

678 SNORD90 in-vitro knock-down

- 679 SNORD90 was knocked down using antisense oligonucleotides (ASO) containing 2'-O-
- 680 methylations and phosphorothioate-modified nucleotides (supplementary table 9). Four ASOs
- and one scrambled control ASO were screened to identify which achieved the best knock-down
- of SNORD90 (supplementary figure 4). NPCs were plated in 24-well plates until ~90%
- 683 confluent before transfection with ASO (50nM final concentration) using Lipofectamine 2000
- 684 (ThermoFisher) following manufacturer's protocol. NPCs were incubated for 48 hours before
- harvesting for RNA extraction. RNA extraction, cDNA synthesis, and RT-qPCR were as
- 686 described above. One-way ANOVA was used as described above
- 687

688 <u>SNORD90 in-vitro over-expression</u>

- 689 Constructs and cloning were as described above with the following sequences:
- 690 SNORD90 sequence:
- 691 5'TTATAAGTTTTCTAAGTGTCTAATGATGAATTTCATAGGGCAGATTCTGAGGTGAA
- 692 AATTTAATTCATCACTGATACTCCTACTGTGGAATCTGAAGACACTTGAAAACGT 3'
- 693
- 694 Seed Scrambled sequence:
- 695 5'TTATAAGTTTTCTAAGTGTCTAATGATGAATTTCATAGGGCAGATTCTGAAATAAT
- 696 ACTTCGCTTAAGATATTCGACTCCTACTGTGGAATCTGAAGACACTTGAAAACGT 3'
- 697

698 Scrambled sequence:

699 5'GATTCATAATGAGTTGATTTAATCACATGCTGGCTCTCATTCGACCAGAATTTCTCT 700 AGTTGATAAAAGTAAACCAATGAATTAGTATGTTTGATCAAGATGTATGACTCG 3' 701

- NPCs were plated in 24-well plates until ~90% confluent before being transfected with each
- vector using Lipofectamine 2000 (ThermoFisher) following manufacturer's protocol. NPCs were
- incubated for 48 hours before harvesting for RNA extraction. RNA extraction, cDNA synthesis,
- and RT-qPCR were as described above. One-way ANOVA was used as described above.
- 706

707 Target Blockers

- 708 Modified RNA oligos containing 2'-O-methylations and phosphorothioate-modified nucleotides
- 709 (target blockers) were designed against three regions on the NRG3 transcript where SNORD90 is
- 710 predicted to bind (Figure 3A). Target blockers were co-transfected (30nM final concentration)
- vith SNORD90 OE vectors using lipofectamine 2000 following manufacturer recommendations
- for "plasmid DNA and siRNA" co-transfection. For groups where target blockers were pooled
- together, equal amounts for each target blocker were used totaling 30nM final concentration.
- 714 NPC culture conditions, RNA extraction, cDNA synthesis, and RT-qPCR were as described
- above. One-way ANOVA was used as described above.
- 716

717 Western blot

718 Cell pellets from cell culture were lysed in lysis buffer [150 mM NaCl, 50 mM HEPES (pH 7),

50 mM EDTA, and 0.1% NP-40] and quantified using PierceTM BCA Protein Assay Kit (Thermo

720 Fisher). Equal amounts of proteins were electrophoresed on 4-20% Mini-PROTEAN TGX Stain-

721	Free Gels (Bio Rad). Proteins were then transferred onto nitrocellulose membranes using the
722	Trans-Blot Turbo Transfer System (Bio Rad). The membranes were blocked with 5% Bovine
723	Serum Albumin (BSA) in Phosphate-Buffered Saline (0.05% Tween 20) (PBS-T) at room
724	temperature for 1-2 hrs and then incubated with primary antibody (NRG3 (ab109256) at 1:500
725	and GAPDH (3683S) at 1:1000) in 1% BSA in PBS-T overnight at 4 °C. They were then
726	incubated with either biotin-conjugated anti-rabbit antibody (BA-1000) or with Horseradish
727	Peroxidase (HRP)-conjugated anti-rabbit antibody diluted 1:5000 in 1% BSA in PBS-T for 1 hr
728	at room temperature. The membranes that were incubated with biotin-conjugated anti-rabbit
729	antibody were washed with PBS-T and incubated with streptavidin-conjugated HRP (016-030-
730	084) at 1:5000 in 1% NFDM in PBS-T for 1 hr at room temperature. After washing,
731	immunoreactivity was detected using enhanced chemiluminescence solutions (ECL) and the
732	Biorad ChemiDoc TM MP imaging system. Western blots were performed in 3 biological
733	replicates.

734

735 **<u>RNA immunoprecipitation</u>**

736 Overexpression of SNORD90 and scramble were performed as described above. RNA 737 immunoprecipitation (RIP) was performed using the Magna RIP RNA-Binding Protein 738 Immunoprecipitation kit (Millipore Sigma) following the manufacturer's protocol with slight 739 modifications. NPCs were collected and lysed in complete RIP lysis buffer. 10 uL of cell extract was stored at -80°C and used as input. NPC extracts were incubated in RIP buffer containing 740 741 magnetic beads conjugated to anti-fibrillarin antibody (ab226178; abcam), anti-RBM15B 742 antibody (22249-1-AP; proteintech), or IgG control (provided by the kit) overnight in 4°C. Bead 743 complexes were washed 6 times with RIP buffer and eluted directly in TRIzol. RNA from all

conditions were purified in parallel using the RNA microPrep kit (Zymol) and eluted into 15 μL
H2O. The entire eluate was transcribed to cDNA using M-MLV Reverse Transcriptase
(200 U/μL) (ThermoFisher) with random hexamers. RT-qPCR was as described above.

747

748 <u>m6A-RIP</u>

749 m6A-RIP protocol was as described by Engel et al., with minor modifications. 3 µg total RNA 750 was mixed with 3 fmol spike-in and equally split into 3 conditions: m6A-RIP, IgG control and 751 input. Input samples were frozen and kept at -80C during the m6A-RIP protocol. m6A-RIP and 752 IgG control samples were incubated with 1 µg anti-m6A antibody (rabbit polyclonal 202 003, 753 Synaptic Systems) or 1 µg normal rabbit IgG (NEB) in immunoprecipitation (IP) buffer (10 mM 754 Tris-HCl [pH 7.5], 150 mM NaCl, 0.1% IGEPAL CA-630 in nuclease-free H2O, 0.5 mL total 755 volume) with 1 µL RNasin Plus (Promega) rotating head over tail at 4°C for 2 hrs, followed by 756 incubation with 2x washed 25 µL Dynabeads M-280 (Sheep anti-Rabbit IgG Thermo Fisher 757 Scientific) rotating head over tail at 4°C for 2 hrs. Bead-bound antibody-RNA complexes were 758 recovered on a magnetic stand and washed in the following order: twice with IP buffer, twice 759 with high-salt buffer (10 mM Tris-HCl [pH 7.5], 500 mM NaCl, 0.1% IGEPAL CA-630 in 760 nuclease-free H2O), and twice with IP buffer. RNA was eluted directly into TRIzol and input 761 RNA was also taken up in TRIzol. RNA from all conditions was purified in parallel using the 762 RNA microPrep (Zymol) and eluted into 15 µL H2O. The entire eluate was transcribed to cDNA 763 using M-MLV Reverse Transcriptase (200 U/ μ L) (ThermoFisher) with random hexamers. RT-764 qPCR was as described above. One-way ANOVA was used as described above

765

766 Spike-in

767	A spike-in Oligo was used as a normalizer for quantitative RT-PCR. The spike-in oligo was
768	100nt in length with 3 internal m6A/m sites within GGAC motif flanked by the most frequent
769	nucleotides 5' U/A, 3' A/U, not complementary to hsa or mmu RefSeq mRNA or genome,
770	secondary structure exposing m6A sites (as described by Engel et al., 2018). The sequence is:
771	GCAGAACCUAGUAGCGUGUGGmACACGAACAGGUAUCAAUAUGCGGGUAUGGmA
772	CUAAAGCAACGUGCGAGAUUACGCUGAGGmACUACAAUCUCAGUUACCA
773	(synthesized by Horizon Discoveries).
774	
775	Dicer-Substrate Short Interfering RNA (dsiRNA) gene silencing
776	DsiRNAs KD was assessed via RT-qPCR in the final experimental samples (supplementary
777	figure 8). In each silencing condition, the siRNA sequences were specific to the m6a reader of
778	interest, as shown by the quantitative RT-PCR data (supplementary figure 8). Cells were seeded
779	in 24-well plates and grown to \sim 70% confluency. 50nM siRNA was transfected using
780	lipofectamine 2000 according to the manufacturer's instructions. A second transfection was
781	performed 48hrs after the first transfection. Following the second round of dsiRNA transfection,
782	SNORD90 OE vectors were transfected 48 hours later. NPCs were then collected 48 hours after
783	the third transfection. DsiRNA sequences and oligos were provided by IDT (supplementary table
784	10). RNA extraction, cDNA synthesis, and RT-qPCR were as described above. One-way
785	ANOVA was used as described above
786	
787	Electrophysiological Recording
788	Brain slices preparation

789 Mice were stereotactically injected with SNORD90-OE or SNORD90-Scramble viral vector as790 described above.

791

792 3 weeks after the injection, mice received an overdose injection of pentobarbital (100 mg/kg i.p.) 793 and were perfused with carbogenated (95% O₂, 5% CO₂) ice-cold slicing solution containing (in 794 mM): 2.5 KCl, 11 glucose, 234 sucrose, 26 NaHCO₃, 1.25 NaH₂PO₄, 10 MgSO₄, 2 CaCl₂; pH 795 7.4, 340 mOsm. After decapitation, 300 µm coronal slices containing the ACC were prepared in 796 carbogenated ice-cold slicing solution using a vibratome (Leica VT 1200S) and allowed to recover for 20 min at 33°C in carbogenated high osmolarity artificial cerebrospinal fluid (high-797 798 Osm aCSF) containing (in mM): 3.2 KCl, 11.8 glucose, 132 NaCl, 27.9 NaHCO₃, 1.34 799 NaH₂PO₄, 1.07 MgCl₂, 2.14 CaCl₂; pH 7.4, 320 mOsm) followed by 40 min incubation at 33°C 800 in carbogenated aCSF containing (in mM): 3 KCl, 11 glucose, 123 NaCl, 26 NaHCO₃, 1.25 NaH₂PO₄, 1 MgCl₂, 2 CaCl₂; pH 7.4, 300 mOsm. Subsequently, slices were kept at room 801 802 temperature (RT) in carbogenated aCSF until use.

803

804 Patch-clamp recordings

Slices were then transferred in the recording chamber and superfused (4-5 mL/min) with carbogenated aCSF and recordings performed at RT. Pyramidal neurons of the ACC were visualized with infrared differential interference contrast (DIC) microscopy (BX51W1, Olympus) and an Andor Neo sCMOS camera (Oxford Instruments, Abingdon, UK). Somatic whole-cell voltage-clamp recordings from ACC pyramidal neurons (> 1 G Ω seal resistance, -70 mV holding potential) were performed using a Multiclamp 700B amplifier (Molecular Devices, San Jose, CA, USA). Data were acquired using pClamp 10.7 on a personal computer

connected to the amplifier via a Digidata-1440 interface (sampling rate: 20 kHz; low-pass filter: 813 8 kHz). Borosilicate glass pipettes (BF100-58-10, Sutter Instrument, Novato, CA, USA) with 814 resistances 4-6 M Ω were pulled using a laser micropipette puller (P-2000, Sutter Instrument). 815 Data obtained with a series resistance > 20 M Ω or fluctuation more than 20% of the initial values 816 were discarded. 817

For sEPSCs recording, pyramidal neurons were clamped at -70 mV in the presence of BIM
(20 uM) with the pipette solution containing (in mM): 125 Cs-methanesulfonate, 8 NaCl, 10
HEPES, 0.5 EGTA, 4 Mg-ATP, 0.3 Na-GTP, 20 Phosphocreatine and 5 QX-314 (pH 7.2 with
CsOH, 285-290 mOsm).

822

Analysis was performed using ClampFit 10.7 and Easy Electrophysiology V2.2
(https://www.easyelectrophysiology.com), and statistical significance assessed with GraphPad
Prism 7.

826

827 ACKNOWLEDGMENTS: GT holds a Canada Research Chair (Tier 1) and is supported by grants from the Canadian Institute of Health Research (CIHR) (FDN148374, EGM141899, 828 829 ENP161427), and by the Fonds de recherche du Québec -Santé (FRQS) through the Quebec 830 Network on Suicide, Mood Disorders, and Related Disorders. CAN-BIND is an Integrated 831 Discovery Program carried out in partnership with, and financial support from, the Ontario Brain 832 Institute, an independent nonprofit corporation, funded partially by the Ontario government. The opinions, results, and conclusions are those of the authors and no endorsement by the Ontario 833 834 Brain Institute is intended or should be inferred. Additional funding is provided by the Canadian

835	Institutes of Health Research (CIHR). All study medications were independently purchased at
836	wholesale market values. AC is the incumbent of the Vera and John Schwartz Family
837	Professorial Chair in Neurobiology at the Weizmann Institute and the head of the Max Planck
838	Society-Weizmann Institute of Science Laboratory for Experimental Neuropsychiatry and
839	Behavioral Neurogenetics. This work is supported by the German Ministry of Science and
840	Education (IMADAPT, FKZ: 01KU1901); the Ruhman Family Laboratory for Research in the
841	Neurobiology of Stress (AC); research support from Bruno and Simone Licht; the Perlman
842	Family Foundation, founded by Louis L. and Anita M. Perlman (AC); the Adelis Foundation
843	(AC); and Sonia T. Marschak (AC). JPL holds postdoctoral fellowships from the European
844	Molecular Biology Organization (EMBO-ALTF 650-2016), Alexander von Humboldt
845	Foundation, and the Canadian Biomarker Integration Network in Depression (CAN-BIND). J.D
846	is the incumbent of the Achar Research Fellow Chair in Electrophysiology.
847	

848 AUTHOR CONTRIBUTIONS: RL and GT conceptualized the project with input from AC, 849 JPL AK, and LMF. JPL performed small RNA sequencing from human clinical samples. PB, FF, 850 BNF, RWL, RM, DJM, SVP, CS, RU, JAF, and SHK participated in the design the sample 851 accusation of the human clinical trials. RL and LMF performed small RNA sequencing on 852 human post-mortem brain samples. CN and NM contributed to the collection of the human-853 postmortem samples and molecular analysis. ZA provided bioinformatic support for analysis of 854 sequencing data. AK performed mouse behavioral experiments. ECI and CB provided mouse ACC samples. JD performed electrophysiology experiments; YJB performed surgeries with 855 856 input from AK and JPL. TPW provided input on electrophysiology experiments. PI performed 857 western blots. RL performed cell culture experiments with input from JY. RL and HH performed

858	m6A experiments.	RL and GT	wrote the manus	cript with input	from AK,	JPL, JD, JBF,	TPW,
-----	------------------	-----------	-----------------	------------------	----------	---------------	------

ECI, CB, PB, FF, BNF, RWL, RM, DJM, SVP, CS, RU, CN, NM, JAF, SHK, and AC.

860

861 **COMPETING INTERESTS:** RM has received consulting and speaking honoraria from

- 862 AbbVie, Allergan, Eisai, Janssen, KYE, Lallemand, Lundbeck, Neomind, Otsuka, and Sunovion,
- and research grants from CAN-BIND, CIHR, Janssen, Lallemand, Lundbeck, Nubiyota, OBI and
- 864 OMHF. JAF has received consulting and speaking fees from Takeda and RBH, and research
- funding from NSERC, CIHR, and OBI.


866

867 **REFERENCES:**


- B. J. Brody, Q. Gu, Antidepressant Use Among Adults: United States, 2015-2018. NCHS
 Data Brief, 1-8 (2020).
- A. Cipriani *et al.*, Comparative efficacy and acceptability of 21 antidepressant drugs for
 the acute treatment of adults with major depressive disorder: a systematic review and
 network meta-analysis. *Lancet* 391, 1357-1366 (2018).
- 873 3. C. J. Harmer, R. S. Duman, P. J. Cowen, How do antidepressants work? New
 874 perspectives for refining future treatment approaches. *Lancet Psychiatry* 4, 409-418
 875 (2017).
- 876 4. S. B. Ross, A. L. Renyi, Inhibition of the uptake of tritiated 5-hydroxytryptamine in brain tissue. *Eur J Pharmacol* 7, 270-277 (1969).
- J. Vetulani, F. Sulser, Action of various antidepressant treatments reduces reactivity of
 noradrenergic cyclic AMP-generating system in limbic forebrain. *Nature* 257, 495-496
 (1975).
- 881 6. R. M. Berman *et al.*, Antidepressant effects of ketamine in depressed patients. *Biol Psychiatry* 47, 351-354 (2000).
- R. S. Duman, Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide. *F1000Res* 7, (2018).
- 885 8. G. Bonanno *et al.*, Chronic antidepressants reduce depolarization-evoked glutamate
 886 release and protein interactions favoring formation of SNARE complex in hippocampus.
 887 *J Neurosci* 25, 3270-3279 (2005).
- 888 9. L. Musazzi, G. Treccani, A. Mallei, M. Popoli, The action of antidepressants on the
 glutamate system: regulation of glutamate release and glutamate receptors. *Biol*890 *Psychiatry* 73, 1180-1188 (2013).
- H. S. Mayberg *et al.*, Deep brain stimulation for treatment-resistant depression. *Neuron*45, 651-660 (2005).

893	11.	M. Roet et al., Deep Brain Stimulation for Treatment-Resistant Depression: Towards a
894		More Personalized Treatment Approach. J Clin Med 9, (2020).
895	12.	M. Herve et al., Translational Identification of Transcriptional Signatures of Major
896		Depression and Antidepressant Response. Front Mol Neurosci 10, 248 (2017).
897	13.	L. Lestrade, M. J. Weber, snoRNA-LBME-db, a comprehensive database of human
898		H/ACA and C/D box snoRNAs. Nucleic Acids Res 34, D158-162 (2006).
899	14.	C. Ender et al., A human snoRNA with microRNA-like functions. Mol Cell 32, 519-528
900		(2008).
901	15.	S. Kishore, S. Stamm, The snoRNA HBII-52 regulates alternative splicing of the
902		serotonin receptor 2C. Science 311, 230-232 (2006).
903	16.	E. Sharma, T. Sterne-Weiler, D. O'Hanlon, B. J. Blencowe, Global Mapping of Human
904		RNA-RNA Interactions. <i>Mol Cell</i> 62 , 618-626 (2016).
905	17.	S. Kehr, S. Bartschat, P. F. Stadler, H. Tafer, PLEXY: efficient target prediction for box
906		C/D snoRNAs. Bioinformatics 27, 279-280 (2011).
907	18.	C. Paterson et al., Temporal, Diagnostic, and Tissue-Specific Regulation of NRG3
908		Isoform Expression in Human Brain Development and Affective Disorders. Am J
909	10	<i>Psychiatry</i> 174 , 256-265 (2017).
910	19.	Y. N. Wang <i>et al.</i> , Controlling of glutamate release by neuregulin3 via inhibiting the
911	•	assembly of the SNARE complex. <i>Proc Natl Acad Sci U S A</i> 115 , 2508-2513 (2018).
912	20.	D. Zhang <i>et al.</i> , Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds
913	0.1	and activates ErbB4. Proc Natl Acad Sci U S A 94, 9562-9567 (1997).
914	21.	M. Falaleeva <i>et al.</i> , Dual function of C/D box small nucleolar RNAs in rRNA
915		modification and alternative pre-mRNA splicing. <i>Proc Natl Acad Sci U S A</i> 113 , E1625-
916	22	1634 (2016).
917 018	22.	L. P. Benoit Bouvrette, S. Bovaird, M. Blanchette, E. Lecuyer, oRNAment: a database of
918 010		putative RNA binding protein target sites in the transcriptomes of model species. <i>Nucleic</i>
919 920	22	<i>Acids Res</i> 48 , D166-D173 (2020). E. L. Van Nostrand <i>et al.</i> , A large-scale binding and functional map of human RNA-
920 921	23.	binding proteins. <i>Nature</i> 583 , 711-719 (2020).
921	24.	D. P. Patil <i>et al.</i> , m(6)A RNA methylation promotes XIST-mediated transcriptional
923	27.	repression. <i>Nature</i> 537 , 369-373 (2016).
924	25.	D. Tollervey, H. Lehtonen, M. Carmo-Fonseca, E. C. Hurt, The small nucleolar RNP
925	23.	protein NOP1 (fibrillarin) is required for pre-rRNA processing in yeast. <i>EMBO J</i> 10, 573-
926		583 (1991).
927	26.	D. Tollervey, H. Lehtonen, R. Jansen, H. Kern, E. C. Hurt, Temperature-sensitive
928	20.	mutations demonstrate roles for yeast fibrillarin in pre-rRNA processing, pre-rRNA
929		methylation, and ribosome assembly. <i>Cell</i> 72 , 443-457 (1993).
930	27.	J. Kufel, P. Grzechnik, Small Nucleolar RNAs Tell a Different Tale. <i>Trends Genet</i> 35 ,
931		104-117 (2019).
932	28.	S. Ke et al., m(6)A mRNA modifications are deposited in nascent pre-mRNA and are not
933		required for splicing but do specify cytoplasmic turnover. Genes Dev 31, 990-1006
934		(2017).
935	29.	K. D. Meyer, S. R. Jaffrey, Rethinking m(6)A Readers, Writers, and Erasers. Annu Rev
936		<i>Cell Dev Biol</i> 33 , 319-342 (2017).
937	30.	S. Zaccara, S. R. Jaffrey, A Unified Model for the Function of YTHDF Proteins in
938		Regulating m(6)A-Modified mRNA. Cell 181, 1582-1595 e1518 (2020).

939 940	31.	S. Zaccara, R. J. Ries, S. R. Jaffrey, Reading, writing and erasing mRNA methylation. <i>Nat Rev Mol Cell Biol</i> 20 , 608-624 (2019).
940 941	32.	L. A. Farrelly <i>et al.</i> , Histone serotonylation is a permissive modification that enhances
941 942	52.	TFIID binding to H3K4me3. <i>Nature</i> 567 , 535-539 (2019).
942 943	33.	T. Ideue, K. Hino, S. Kitao, T. Yokoi, T. Hirose, Efficient oligonucleotide-mediated
945 944	55.	
944 945		degradation of nuclear noncoding RNAs in mammalian cultured cells. <i>RNA</i> 15 , 1578-1587 (2009).
	24	
946	34.	D. R. Newman, J. F. Kuhn, G. M. Shanab, E. S. Maxwell, Box C/D snoRNA-associated
947		proteins: two pairs of evolutionarily ancient proteins and possible links to replication and
948	25	transcription. RNA 6, 861-879 (2000).
949	35.	D. G. Dimitrova, L. Teysset, C. Carre, RNA 2'-O-Methylation (Nm) Modification in
950	26	Human Diseases. Genes (Basel) 10, (2019).
951	36.	G. Bartolini <i>et al.</i> , Neuregulin 3 Mediates Cortical Plate Invasion and Laminar Allocation
952		of GABAergic Interneurons. <i>Cell Rep</i> 18 , 1157-1170 (2017).
953	37.	J. P. Lopez <i>et al.</i> , MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of
954		antidepressant response and regulate MAPK/Wnt-system genes. <i>Nat Commun</i> 8 , 15497
955	•	(2017).
956	38.	S. H. Kennedy et al., Symptomatic and Functional Outcomes and Early Prediction of
957		Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy
958		in Patients With Major Depressive Disorder: A CAN-BIND-1 Report. J Clin Psychiatry
959		80, (2019).
960	39.	F. Jollant et al., Neural and molecular correlates of psychological pain during major
961		depression, and its link with suicidal ideas. Prog Neuropsychopharmacol Biol Psychiatry
962		100 , 109909 (2020).
963	40.	A. Kassambara. (R package version 0.6.0., 2020).
964	41.	A. Dumais et al., Risk factors for suicide completion in major depression: a case-control
965		study of impulsive and aggressive behaviors in men. Am J Psychiatry 162, 2116-2124
966		(2005).
967	42.	L. M. Fiori et al., miR-323a regulates ERBB4 and is involved in depression. Mol
968		<i>Psychiatry</i> 26 , 4191-4204 (2021).
969	43.	J. Lu et al., Generation of serotonin neurons from human pluripotent stem cells. Nat
970		<i>Biotechnol</i> 34 , 89-94 (2016).
971	44.	J. P. Lopez et al., miR-1202 is a primate-specific and brain-enriched microRNA involved
972		in major depression and antidepressant treatment. Nat Med 20, 764-768 (2014).
973	45.	J. P. Guilloux, M. Seney, N. Edgar, E. Sibille, Integrated behavioral z-scoring increases
974		the sensitivity and reliability of behavioral phenotyping in mice: relevance to
975		emotionality and sex. J Neurosci Methods 197, 21-31 (2011).
_		
976		
977		









- 987 increased expression after eight weeks of antidepressant treatment specifically in those who
- 988 responded. C Snord90 expression in the ACC of mice that underwent unpredictable chronic mild
- 989 stress (UCMS) and antidepressant administration. D SNORD90 expression in human post-
- 990 mortem ACC. Samples were separated based on presence or absence of antidepressant drug
- 991 treatment. E SNORD90 expression in human neuronal cultures exposed to various psychotropic
- 992 drugs. C-E Statistical analysis using one-way ANOVA with Bonferroni post-hoc (unless
- 993 otherwise indicated on the graph). B-E All bar plots represent the mean with individual data
- 994 points as dots. Error bars represent S.E.M. (*p<0.05, **p<0.01, ***p<0.001).

996



998

- **Figure 2:** SNORD90 over-expression in mouse Cg1/2 induces anxiolytic and anti depressive-
- 1000 like behaviors
- 1001 A Timeline of experimental procedure with time (weeks) in relation to behavioral testing.
- 1002 Surgery for viral injection was performed followed by three weeks of recovery before behavioral
- 1003 testing (left). Coronal diagram of the mouse brain representing viral injection site (center).
- 1004 Representative images of GFP expression (green) indicating site specific expression of each
- 1005 construct (right). B The open field test showing total distance traveled in meters. C The elevated
- 1006 plus maze test with total time spent in the closed and open arms of the maze. **D** The splash test
- 1007 with total grooming time. E The tail suspension test with total struggling time. F Emotionality z-
- 1008 score integrating the EPM, SPL, and TST. C-G Statistical analysis using student's two-tailed t-
- 1009 test. All bar plots represent the mean with individual data points as dots. Error bars represent
- 1010 S.E.M. (*p<0.05, **p<0.01, ***p<0.001).
- 1011




- 1013
- 1014
- 1015 Figure 3: SNORD90 down-regulates NRG3

1016 A Full sequence of mature SNORD90 transcript with highlighted regions, labeled predicted B.S.

- 1017 1 and predicted B.S. 2, which are predicted to bind to NRG3. Schematic representation of NRG3
- 1018 pre-mRNA transcript indicating regions on NRG3 where SNORD90 is predicted to bind. The
- 1019 color of the bracket corresponds to predicted B.S.-1 or predicted B.S.-2. B Expression of
- 1020 SNORD90 (left) and NRG3 (right) after over-expressing SNORD90 or scrambled controls
- 1021 (right). C Expression of SNORD90 (left) and NRG3 (right) after knocking-down SNORD90


1022	with antisense oligonucleotides (ASO) and scrambled ASO. D Schematic representation of co-
1023	transfection of SNORD90 over-expression vector without target blockers (top) and with target
1024	blockers (bottom). Target blockers were designed to bind to regions SNORD90 is predicted to
1025	bind, consequently blocking SNORD90 from interacting with those regions on NRG3 (bottom).
1026	E Expression of NRG3 after over-expression of SNORD90 and target blockers. Target blockers
1027	were included one site at a time and all three sites together. B-D, F All bar plots represent the
1028	mean with individual data points as dots. Error bars represent S.E.M. All statistical analysis
1029	utilized a one-way ANOVA with Bonferroni post-hoc (*p<0.05, **p<0.01, ***p<0.001).






1035	A Abundance of SNORD90 (left) and canonical snoRNA (SNORD44; right) in RBM15B-IP and
1036	fibrillarin-IP fractions. B Abundance of SNORD90 in RBM15B-IP (left) and fibrillarin-IP (right)
1037	following over-expression of SNORD90 or scramble control. C Abundance of m6A
1038	modifications on NRG3 mRNA (left) and NRG3 pre-mRNA (right) following over-expression of
1039	SNORD90 or scramble controls. D Abundance of m6A modifications on NRG3 mRNA (left)
1040	and NRG3 pre-mRNA (right) following SNORD90 overexpression with target blockers. E
1041	Abundance of m6A modifications on NRG3 (left) and NRG3 expression (right) following
1042	RBM15B knock-down (siRBM15B) or negative control (siControl) and SNORD90 over-
1043	expression. F Same as E but on NRG3 pre-mRNA. G Expression of NRG3 after knocking-down
1044	m6A reader proteins followed by over-expression of SNORD90. H Schematic overview of
1045	SNORD90 regulation of NRG3 expression. SNORD90 interacts with m6A writer complex in the
1046	nucleus and guides this complex onto NRG3 increasing m6A abundance. The increase in m6A
1047	abundance is not recognized until NRG3 reaches the cytoplasm where it undergoes YTHDF2
1048	mediated RNA decay. All bar plots represent the mean with individual data points as dots. Error
1049	bars represent S.E.M. Statistical analysis utilized as follows: A-B Student's two-tailed t test. E
1050	Pearson correlation. C-D, F-H One-way ANOVA with Bonferroni post-hoc (*p<0.05, **p<0.01,
1051	***p<0.001).

1053



1055



1057 neurotransmission

- **1058** A qPCR confirmation of Snord90 over-expression in cg1/2. **B** Nrg3 expression after Snord90
- 1059 over-expression. C-E Whole-cell patch-clamp recordings in Cg1/2 acute brain slices from mice
- 1060 over-expressing SNORD90 or scramble control. sEPSCs were recorded from pyramidal neurons
- 1061 at -70 mV. A-C & E Statistical analysis using student's two-tailed T-test. All bar plots represent
- the mean with individual data points as dots. Error bars represent S.E.M. (*p<0.05, **p<0.01,
- 1063 ***p<0.001).

Supplementary Materials for

SNORD90 induces glutamatergic signaling following treatment with monoaminergic antidepressants

Rixing Lin[†], Aron Kos[†], Juan Pablo Lopez, Julien Dine, Pascal Ibrahim, Jennie Yang, Laura M. Fiori, Yair Ben-Efraim, Zahia Aouabed, Haruka Mitsuhashi, Tak Pan Wong, El Cherif Ibrahim, Catherine Belzung, Pierre Blier, Faranak Farzan, Benicio N. Frey, Raymond W. Lam, Roumen Milev, Daniel J. Müller, Sagar V. Parikh, Claudio Soares, Rudolf Uher, Corina Nagy, Naguib Mechawar, Jane A. Foster, Sidney H. Kennedy, Alon Chen*, and Gustavo Turecki*


> [†]These authors contributed equally to this work *Corresponding author. Email: <u>gustavo.turecki@mcgill.ca</u>

This PDF file includes:


Figs. S1 to S10

Other Supplementary Material for this manuscript includes the following:

Table S1 to S10 (.xlsx)




Supplementary Figure 1: SCARNA3 expression in human clinical cohorts (related to figure 1) Log2 fold-change of the expression of SCARNA3 before and after antidepressant treatment for all three clinical cohorts. SCARNA3 displayed inconsistent expression after eight weeks of antidepressant treatment.



Supplementary Figure 2: NRG3 expression negatively correlates with SNORD90 in the context of antidepressant (related to figure 1)

A Nrg3 expression in the ACC of mice that underwent unpredictable chronic mild stress (UCMS) and antidepressant administration. **B** NRG3 expression in human post-mortem ACC.

Samples were separated based on presence or absence of antidepressant drug treatment. **C** NRG3 expression in human neuronal cultures exposed to various psychotropic drugs. **D-F** Correlation between SNORD90 and NRG3 expression in each of the respective experiments listed in A-C. **G-I** SNORD90 (red) and NRG3 (black) fold change in relation to control conditions. SNORD90 and NRG3 displayed the most opposing direction of expression in groups exposed to antidepressants. **A-C** Statistical analysis using one-way ANOVA with Bonferroni post-hoc. **D-F** Pearson correlation. **G-I** Statistical analysis using two-way mixed ANOVA with Bonferroni post-hoc. **A**II bar plots represent the mean with individual data points as dots. Error bars represent S.E.M. (*p<0.05, **p<0.01).




Supplementary Figure 3: SNORD90 over-expression in human NPCs (related to figure 3) A Sequences of each over-expressed transcript. Red indicates scrambled sequence and black indicates wild-type sequence. Yellow highlight indicates where forward and reverse primers bind for qPCR quantification. Over-expression of SNORD90 WT transcript and seed scramble will be detected by our primers however full scramble will not. **B** Image of NPC 48hrs post-transfection. White is the expression of GFP to confirm successful transfection. **C** Quantification of NRG3 protein levels following SNORD90 over-expression. NRG3 protein levels were significantly reduced after SNORD90 over-expression (left). Western blots where samples were equally

distributed between two separate gels and randomly assigned a well (right). **D** Expression of NRG3 pre-mRNA following SNORD90 over-expression. **C-D** Statistical analysis using one-way ANOVA with Bonferroni post-hoc. All bar plots represent the mean with individual data points as dots. Error bars represent S.E.M. (*p<0.05, **p<0.01).

Supplementary Figure 3C-source data


Source data for western blots for supplementary figure 3C including original unedited files of each western blot.

A




Supplementary Figure 4: SNORD90 knock-down in human NPCs (related to figure 3)

A Schematic diagram indicating where each ASO is designed to bind onto SNORD90. **B** Screen of all four ASOs to determine which ASO produced the best knock-down of SNORD90. **C** Expression of NRG3 pre-mRNA after SNORD90 knock-down. **B-C** Statistical analysis using one-way ANOVA with Bonferroni post-hoc (unless otherwise indicated on the graph). All bar plots represent the mean with individual data points as dots. Error bars represent S.E.M. (*p<0.05).




Supplementary Figure 5: SNORD90 over-expression and NRG3 target blockers (related to figure 3)

Expression of NRG3 pre-mRNA after SNORD90 over-expression followed by NRG3 target blockers. Statistical analysis using one-way ANOVA with Bonferroni post-hoc (unless otherwise indicated on the graph). All bar plots represent the mean with individual data points as dots. Error bars represent S.E.M.




Supplementary Figure 6: m6A abundance on NRG3 is related to expression (related to figure4)

A Correlation of total m6A abundance on NRG3 and NRG3 expression. **B** Correlation of total m6A abundance on NRG3 pre-mRNA and NRG3 pre-mRNA expression. **A-B** person correlation




Supplementary Figure 7: RBM15B knock-down (related to figure 4)

A qPCR validation of RBM15B knock-down using dsiRNAs. **B-C** Correlation of total m6A abundance on NRG3 or NRG3 pre-mRNA and expression. **B-C** Person correlation. **A** Statistical analysis using one-way ANOVA with Bonferroni post-hoc. All bar plots represent the mean with individual data points as dots. Error bars represent S.E.M. (**p<0.01).




Supplementary Figure 8: m6A-reader knock-down (related to figure 4)

A-E qPCR validation of each respective m6A-reader knock-down using dsiRNAs. **A-E** Statistical analysis using one-way ANOVA with Bonferroni post-hoc. All bar plots represent the mean with individual data points as dots. Error bars represent S.E.M. (* p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).



Supplementary Figure 9: Expression of NRG3 pre-mRNA after m6A-reader knock-down (related to figure 4)

Expression of NRG3 pre-mRNA following m6A-reader knock-down and SNORD90 overexpression. Statistical analysis using one-way ANOVA with Bonferroni post-hoc. All bar plots represent the mean with individual data points as dots. Error bars represent S.E.M. (**p<0.01).



Supplementary Figure 10: Snord90-nrg3 interaction is conserved in mice (related to figure 5) Schematic diagram showing predicted interaction sites between Snord90 and Nrg3 in mice

Supplementary Table 1 to 10

Supp. Table 1 (separate file). Summary statistics for small RNA sequencing analysis in human clinical discovery cohort

Supp. Table 2 (separate file). Summary statistics for small RNA sequencing analysis in human

clinical replication 1 cohort

Supp. Table 3 (separate file). Summary statistics for small RNA sequencing analysis in human

clinical replication 2 cohort

Supp. Table 4 (separate file). SNORD90 BLAST alignment results

Supp. Table 5 (separate file). SNORD90 PLEXY target prediction results (human)

Supp. Table 6 (separate file). SNORD90 RNA binding protein motif prediction results

Supp. Table 7 (separate file). SNORD90 PLEXY target prediction results (mouse)

Supp. Table 8 (separate file). qPCR primer sequences

Supp. Table 9 (separate file). ASO sequences

Supp. Table 10 (separate file). dsiRNA sequences